Night Blindness Treatment Market Report 2026

Night Blindness Treatment Market Overview

• Night Blindness Treatment market size has reached to $4.2 billion in 2025 • Expected to grow to $5.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Impact Of Increasing Cataract Prevalence On The Night Blindness Treatment Market • Market Trend: Innovative Genetic Therapies Revolutionizing Night Blindness Treatment Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Night Blindness Treatment Market?

Night blindness treatment refers to interventions aiming to alleviate conditions such as vitamin A deficiency and other issues impairing vision in low light settings. It aims to enhance visual acuity in dim conditions and improve overall visual function by addressing underlying causes. The purpose of night blindness treatment is to improve the patient's ability to see in low-light conditions and at night. This treatment aims to address the underlying causes of night blindness and alleviate the symptoms. The main treatments in the night blindness treatment market are medication, surgery, and other treatments. Night blindness medication refers to treatments aimed at improving vision in low-light conditions, often targeting underlying conditions such as vitamin A deficiency, retinitis pigmentosa, or other retinal disorders. Night blindness can be diagnosed with blood tests, color vision testing, pupil light reflex, refraction, retinal exam, electroretinogram (ERG), and others. The symptoms include eye pain, vomiting, cloudy vision, halos, light sensitivity, distance vision problem, headache, and others. The end users are clinic, hospital, and others.

What Is The Night Blindness Treatment Market Growth Forecast?

The night blindness treatment market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising investment in eye health programs, increasing demand for personalized treatments, expansion of gene therapy applications, growth in healthcare infrastructure, improving reimbursement policies. Major trends in the forecast period include rising prevalence of vitamin A deficiency, increasing adoption of early diagnosis techniques, growth in minimally invasive eye surgeries, expanding use of nutritional and preventive therapies, improved access to vision care in emerging economies.

Global Night Blindness Treatment Market Segmentation

1) By Treatment: Medication, Surgery, Other Treatments 2) By Diagnosis: Blood Tests, Color Vision Testing, Pupil Light Reflex, Refraction, Retinal Exam, Electroretinogram (ERG), Other Diagnoses 3) By Symptom: Eye Pain, Cloudy Vision, Halos, Light Sensitivity, Distance Vision Problem, Other Symptoms 4) By End User: Clinic, Hospital, Other End Users Subsegments: 1) By Medication: Vitamin A Supplements, Retinoid Therapy, Beta-Carotene Supplements, Anti-Glaucoma Medications 2) By Surgery: Cataract Surgery, Retinal Surgery, Corneal Transplantation, LASIK Surgery 3) By Other Treatments: Light Therapy, Gene Therapy, Low Vision Aids And Assistive Devices, Nutritional Therapy

What Is The Driver Of The Night Blindness Treatment Market?

The increasing prevalence of cataracts is expected to propel the growth of the night blindness treatment market going forward. Cataracts refer to a condition where the eye's lens becomes cloudy, leading to impaired vision. The increased exposure to ultraviolet (UV) light from the sun, smoking, and poor diet contribute to the development of cataracts. Cataracts reduce the eye's ability to distinguish between different shades of light and dark, which is crucial for night vision. This decreased contrast sensitivity makes navigating and recognizing objects in low-light environments harder. For instance, in May 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, hospital admissions for cataract surgery in England rose to more than 516,000 in the financial year ending 2023 equivalent to 4,679 per 100,000 people marking a significant increase from the prior year’s rate of 3,803 per 100,000. Therefore, the increasing prevalence of cataracts is driving the night blindness treatment industry.

Key Players In The Global Night Blindness Treatment Market

Major companies operating in the night blindness treatment market are Johnson & Johnson Private Limited, Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc, Bausch Health Companies Inc, Cipla Inc, Nature’s Way, Garden of Life, Apellis Pharmaceuticals Inc, Solgar, Acucela Inc, Swanson Health Products, Astellas Pharma Inc, F. Hoffmann‑La Roche Ltd, Applied Genetic Technologies Corp, MeiraGTx Holdings plc, GenSight Biologics, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Opthea Limited, Oxurion NV, EyePoint Pharmaceuticals Inc, Ocuphire Pharma Inc.

Global Night Blindness Treatment Market Trends and Insights

Major companies operating in the night blindness treatment market are developing innovative genetic therapies to address the underlying genetic mutations responsible for enhancing treatment efficacy for improved patient outcomes. Genetic therapies help in treating night blindness by targeting and repairing specific genetic mutations that affect retinal function, potentially restoring vision in individuals with inherited retinal disorders such as retinitis pigmentosa. For instance, in August 2023, HuidaGene Therapeutics., a US-based clinical-stage biotechnology company, introduced HG004, a gene therapy designed to treat inherited retinal diseases such as Leber's congenital amaurosis. This therapy has shown superiority over existing treatments in preclinical studies, aiming to restore retinal function and alleviate night blindness and other conditions associated with RPE65-induced impairments.

What Are Latest Mergers And Acquisitions In The Night Blindness Treatment Market?

In October 2025, AviadoBio Ltd., a UK-based developer of targeted gene therapies for neurodegenerative and ocular conditions, entered into an exclusive option-license agreement with UgeneX Therapeutics to advance and potentially commercialize UGX-202, an optogenetics-based gene therapy designed to restore vision in patients with retinitis pigmentosa and other inherited retinal diseases. With this agreement, AviadoBio aims to expand its next-generation ocular gene therapy portfolio by leveraging UgeneX’s optimized AAV-based optogenetic platform to address profound photoreceptor loss and associated night blindness. UgeneX Therapeutics is a China-based biotechnology company specializing in gene therapy innovations for ophthalmic diseases, supported by a proprietary platform and a growing pipeline of retinal gene therapy candidates.

Regional Outlook

North America was the largest region in the night blindness treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Night Blindness Treatment Market?

The night blindness treatment market consists of revenues earned by entities by providing services such as diagnostic services, medical management and consultation, surgical interventions, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The night blindness treatment market also includes sales of night vision goggles, retinal implants and prosthetics, electroretinography (ERG) systems, vitamin A supplements, and intraocular injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Night Blindness Treatment Market Report 2026?

The night blindness treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the night blindness treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.